<DOC>
	<DOCNO>NCT02588339</DOCNO>
	<brief_summary>This study test PANO combination tacrolimus/sirolimus ( TAC/SIR ) acute GVHD prevention . The purpose study determine Panobinostat ( PANO ) use combination sirolimus tacrolimus help reduce incidence Graft-vs-host disease ( GVHD ) .</brief_summary>
	<brief_title>Panobinostat ( LBH589 ) : Acute Graft Versus Host Disease ( aGVHD ) Prevention</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Age ≥ 18 year old time enrollment Signed informed consent Hematologic disorder require allogeneic hematopoietic cell transplantation Left ventricular ejection fraction ( LVEF ) ≥ 45 % multiple uptake gate acquisition ( MUGA ) scan echocardiogram Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) , diffuse lung capacity oxygenation ( DLCO ) adjust ≥ 50 % predict value pulmonary function test Transaminases ( AST , ALT ) &lt; 3 time upper limit normal ( ULN ) value Creatinine clearance calculate ≥ 50 mL/min Karnofsky Performance Status Score ≥ 60 % . Human leukocyte antigen ( HLA ) match 8/8 ( A , B , C , DRB1 ) relate unrelated donor Active infection control appropriate antimicrobial therapy HIV , hepatitis B ( HBcAb positive HBsAg negative undetectable viral load eligible ) , hepatitis C infection Sorror 's comorbidity factor total score &gt; 4 . Important modification comorbidity index calculation : DLCO adjust include assessment pulmonary risk , except patient DLCO adjust &lt; 50 % excluded trial . Antithymocyte globulin ( ATG ) part condition regimen Cyclophosphamide part condition regimen GVHD prophylaxis Pregnancy Histone deacetylase ( HDAC ) , DAC , HSP90 inhibitor valproic acid treatment cancer within 30 day Patients need valproic acid medical condition study within 5 day prior first PANO treatment Impaired cardiac function clinically significant cardiac disease , include one following : Any history ventricular fibrillation torsade de pointes ; Bradycardia define heart rate ( HR ) &lt; 45 bpm ( Patients pacemaker eligible HR ≥ 45 bpm ) ; Screening electrocardiogram ( ECG ) QTcF &gt; 480 msec ; Right bundle branch block + leave anterior hemiblock ( bifascicular block ) ; Patients myocardial infarction unstable angina ≤ 12 month prior start study drug ; Other clinically significant heart disease ( e.g. , New York Heart Association ( NYHA ) class III IV , uncontrolled hypertension ) per discretion principal investigator and/or treat physician ; Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug exception drug list Appendix B study document require hematopoietic cell transplantation ( HCT ) patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hematologic disorder</keyword>
	<keyword>allogeneic hematopoietic cell transplantation</keyword>
</DOC>